Database / Semaglutide 2.4 mg
Semaglutide 2.4 mg
Wegovy · Novo Nordisk. The benchmark GLP-1 drug, with the longest real-world record and a proven reduction in heart attacks and strokes (SELECT trial).
Average weight loss
16.9%
Stopped for side effects
7%
Trial length
68 wk
Ranking score
4.5
STEP 1 results
Phase 3 · 68 weeks · 2.4 mg weekly
Adults with obesity, no diabetes (n=1,961)
Weight loss
16.9%
Nausea
44.2%
Vomiting
24.8%
Diarrhea
31.5%
Constipation
23.4%
Quit due to side effects
7.0%
n/r = not reported. Counting everyone who started, weight loss was 14.9%. Placebo group: 2.4%.
Worth knowing
- Label includes cardiovascular risk reduction in adults with heart disease.
4.5
GLP-1 Performance Index
Rank 5 of 6 ranked drugs
Stomach = (44.2 + 24.8 + 31.5 + 23.4) ÷ 4
= 31.0
Burden = 31.0 + 1 × 7.0 = 38.0
Index = 16.9 ÷ 38.0 × 10 = 4.45
At a glance
- Company
- Novo Nordisk
- Targets
- GLP-1
- Molecule
- Peptide
- Dosing
- Injection, weekly
- Status
- FDA approved (Jun 2021)